Unlike today's crop of commercially approved CAR-T therapies that rely on viral vectors, GenomeFrontier is pursuing a ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and GenomeFrontier Therapeutics, a Taiwanese cell therapy company developing novel virus-free CAR-T therapies, today ...

Allogene Therapeutics CEO Zach Roberts discusses his work advancing groundbreaking CAR T-cell therapy and his vision for ...

As demand for CAR T therapies grows, modular platforms are offering process development teams new ways to improve cell expansion, recovery and scale-up. Chimeric antigen receptor (CAR) T cell ...

PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...

HCW Biologics Inc. (NASDAQ:HCWB) announced new research published in Science Advances indicating that its compound HCW9206 may improve the production of CAR-T cell therapies. The study was carried out ...

After recalibrating its production strategy in the late 2010s to better meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential ...

As the next generation of CAR T therapies moves closer to broader commercialization, industry leaders say the future will depend less on choosing between ex vivo and in vivo approaches and more on ...

CAR-T’s commercial challenge is making thousands of patient-specific manufacturing runs behave like one reliable system. "In ...

CAR T therapies face scalability challenges. An eXmoor consultant explores how synthetic approaches using lipid nanoparticles ...

Chimeric antigen receptor T cell (CAR T) therapies have transformed the treatment of blood cancers, delivering durable responses in patients with limited options. But CAR T therapies are complex and ...